Tanovea™-CA1 (rabacfosadine for injection) was discovered by Gilead Sciences, Inc., and licensed to VetDC, Inc. for use in companion animal cancer. It is a novel, small molecule drug, designed to specifically target and attack cancer cells implicated in lymphoma, one of the most common cancers affecting pets today. Animal cancer drugs are regulated by the FDA Center for Veterinary Medicine.
In January, 2017, VetDC announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) has granted a conditional approval of Tanovea-CA1 (rabacfosadine for injection) for the treatment of lymphoma in dogs. Tanovea-CA1 is anticipated to be available to veterinarians in the spring of 2017.
When it comes to cancer, you want access to the latest treatments and proven leading edge therapies. We don’t believe that the term “cancer survivor” should be limited to humans, which is why we are dedicated to helping companion animals have a fighting chance.